|
EP2338478B1
(en)
|
2002-06-28 |
2014-07-23 |
Protiva Biotherapeutics Inc. |
Method for producing liposomes
|
|
JP4951338B2
(ja)
*
|
2003-07-16 |
2012-06-13 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質に封入された干渉ｒｎａ
|
|
EP1948674A4
(en)
|
2005-11-02 |
2009-02-04 |
Protiva Biotherapeutics Inc |
MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
|
|
AU2008342535B2
(en)
*
|
2007-12-27 |
2015-02-05 |
Arbutus Biopharma Corporation |
Silencing of polo-like kinase expression using interfering RNA
|
|
JP5475753B2
(ja)
|
2008-04-15 |
2014-04-16 |
プロチバ バイオセラピューティクス インコーポレイティッド |
核酸送達用の脂質製剤
|
|
EP3225621A1
(en)
|
2008-10-09 |
2017-10-04 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
MX338780B
(es)
|
2008-11-10 |
2016-05-02 |
Alnylam Pharmaceuticals Inc |
Lipidos y composiciones novedosas para el suministro de terapeuticos.
|
|
EP2449106B1
(en)
*
|
2009-07-01 |
2015-04-08 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
CA2767127A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
EP3494963A1
(en)
*
|
2009-12-18 |
2019-06-12 |
The University of British Columbia |
Methods and compositions for delivery of nucleic acids
|
|
EP2567952A4
(en)
*
|
2010-04-28 |
2015-11-25 |
Kyowa Hakko Kirin Co Ltd |
CATIONIC LIPID
|
|
US9408914B2
(en)
|
2010-04-28 |
2016-08-09 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
|
EP2569276B1
(en)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
US11291635B2
(en)
|
2010-07-06 |
2022-04-05 |
Glaxosmithkline Biological Sa |
Virion-like delivery particles for self-replicating RNA molecules
|
|
LT3243526T
(lt)
|
2010-07-06 |
2020-02-10 |
Glaxosmithkline Biologicals S.A. |
Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
|
|
HRP20160805T1
(hr)
|
2010-07-06 |
2016-08-12 |
Glaxosmithkline Biologicals Sa |
Imuniziranje velikih sisavaca malim dozama rna
|
|
CA2804396C
(en)
|
2010-07-06 |
2021-06-29 |
Novartis Ag |
Liposomes with lipids having an advantageous pka-value for rna delivery
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
SI3981427T1
(sl)
|
2010-08-31 |
2022-08-31 |
Glaxosmithkline Biologicals S.A. |
Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
CN103269713B
(zh)
|
2010-10-11 |
2016-01-20 |
诺华有限公司 |
抗原递送平台
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
WO2012162210A1
(en)
*
|
2011-05-26 |
2012-11-29 |
Merck Sharp & Dohme Corp. |
Ring constrained cationic lipids for oligonucleotide delivery
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
EP2788006A1
(en)
|
2011-12-07 |
2014-10-15 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
AU2012352180A1
(en)
|
2011-12-16 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US9035039B2
(en)
*
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
CN104125826A
(zh)
*
|
2011-12-22 |
2014-10-29 |
努沃研究有限责任公司 |
亚氯酸盐或氯酸盐脂质体组合物
|
|
AU2013222179B2
(en)
|
2012-02-24 |
2017-08-24 |
Arbutus Biopharma Corporat ion |
Trialkyl cationic lipids and methods of use thereof
|
|
CA2868034C
(en)
|
2012-03-29 |
2021-07-27 |
Shire Human Genetic Therapies, Inc. |
Ionizable cationic lipids
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
AU2013243949A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
HK1207977A1
(en)
|
2012-04-25 |
2016-02-19 |
Trustees Of Tufts College |
Silk microspheres and methods for surface lubrication
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
WO2014164753A1
(en)
*
|
2013-03-11 |
2014-10-09 |
Emory University |
Methods and compositions for managing vascular conditions
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
CN105793425B
(zh)
|
2013-06-17 |
2021-10-26 |
布罗德研究所有限公司 |
使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
AU2014281028B2
(en)
|
2013-06-17 |
2020-09-10 |
Massachusetts Institute Of Technology |
Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
|
|
EP3620524A1
(en)
|
2013-06-17 |
2020-03-11 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
EP3985118A1
(en)
|
2013-11-22 |
2022-04-20 |
MiNA Therapeutics Limited |
C/ebp alpha short activating rna compositions and methods of use
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
CN118813621A
(zh)
|
2013-12-12 |
2024-10-22 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
EP3080257A1
(en)
|
2013-12-12 |
2016-10-19 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
MX374530B
(es)
|
2013-12-12 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de los sistemas y composiciones crispr-cas para actuar sobre hbv y trastornos y enfermedades virales.
|
|
JP6779866B2
(ja)
|
2014-06-13 |
2020-11-04 |
チルドレンズ メディカル センター コーポレイション |
ミトコンドリアを単離するための製品および方法
|
|
CN106795096B
(zh)
|
2014-06-25 |
2020-05-29 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
US10583084B2
(en)
|
2014-06-26 |
2020-03-10 |
Ramot At Tel-Aviv University Ltd. |
Liposomal formulations for delivery of nucleic acids
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US20170210788A1
(en)
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
EP3686279B1
(en)
|
2014-08-17 |
2023-01-04 |
The Broad Institute, Inc. |
Genome editing using cas9 nickases
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
BR112017006679A2
(pt)
|
2014-10-02 |
2017-12-26 |
Protiva Biotherapeutics Inc |
moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3230452B1
(en)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
EP3234192B1
(en)
|
2014-12-19 |
2021-07-14 |
The Broad Institute, Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
|
CA3012631A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
WO2016205613A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
HRP20240865T1
(hr)
|
2015-06-29 |
2024-10-11 |
Acuitas Therapeutics Inc. |
Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
WO2017031370A1
(en)
|
2015-08-18 |
2017-02-23 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
ES2910425T3
(es)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
CN109153980B
(zh)
|
2015-10-22 |
2023-04-14 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
WO2017074788A1
(en)
|
2015-10-27 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
AU2016343803B2
(en)
|
2015-10-28 |
2021-04-29 |
Acuitas Therapeutics, Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017095946A1
(en)
|
2015-11-30 |
2017-06-08 |
Flagship Pioneering, Inc. |
Methods and compositions relating to chondrisomes
|
|
AU2016366978B2
(en)
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
SMT202200252T1
(it)
|
2015-12-22 |
2022-07-21 |
Modernatx Inc |
Composti e composizioni per il rilascio intracellulare di agenti
|
|
HRP20220525T1
(hr)
|
2015-12-23 |
2022-05-27 |
Modernatx, Inc. |
Postupci uporabe polinukleotida koji kodiraju ligand ox40
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
JP7185527B2
(ja)
|
2016-01-15 |
2022-12-07 |
ザ チルドレンズ メディカル センター コーポレーション |
ミトコンドリアおよび組み合わされたミトコンドリア剤の治療的使用
|
|
KR102424476B1
(ko)
|
2016-04-19 |
2022-07-25 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
EP3445856A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
US11286478B2
(en)
|
2016-04-19 |
2022-03-29 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CN109642231A
(zh)
|
2016-06-17 |
2019-04-16 |
博德研究所 |
Vi型crispr直向同源物和系统
|
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
|
MX2018016389A
(es)
*
|
2016-06-30 |
2019-08-16 |
Arbutus Biopharma Corp |
Composiciones y metodos para suministro de arn mensajero.
|
|
EP3500671B1
(en)
|
2016-08-17 |
2024-07-10 |
The Broad Institute, Inc. |
Method of selecting target sequences for the design of guide rnas
|
|
US20200283743A1
(en)
|
2016-08-17 |
2020-09-10 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CA3056133A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
SI3596041T1
(sl)
|
2017-03-15 |
2023-02-28 |
Modernatx, Inc. |
Spojina in sestavki za intracelično dostavljanje terapevtskih sredstev
|
|
US11739308B2
(en)
|
2017-03-15 |
2023-08-29 |
The Broad Institute, Inc. |
Cas13b orthologues CRISPR enzymes and systems
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
EP3596112A2
(en)
|
2017-03-17 |
2020-01-22 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
|
EP3610009A1
(en)
|
2017-04-12 |
2020-02-19 |
The Broad Institute, Inc. |
Novel type vi crispr orthologs and systems
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
|
EP4410317A3
(en)
|
2017-04-28 |
2024-10-30 |
Acuitas Therapeutics Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
CA3062426A1
(en)
|
2017-05-08 |
2018-11-15 |
Flagship Pioneering Innovations V, Inc. |
Compositions for facilitating membrane fusion and uses thereof
|
|
EP3625246A1
(en)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
|
EP3625342B1
(en)
|
2017-05-18 |
2022-08-24 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
JP2020524993A
(ja)
|
2017-06-13 |
2020-08-27 |
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド |
クロンを含む組成物及びその使用
|
|
WO2018232006A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Polynucleotides encoding coagulation factor viii
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP3668834B1
(en)
|
2017-08-17 |
2024-10-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
EP4219715A3
(en)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
US11447773B2
(en)
|
2017-09-08 |
2022-09-20 |
Mina Therapeutics Limited |
Stabilized HNF4A saRNA compositions and methods of use
|
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
US20200255828A1
(en)
|
2017-10-04 |
2020-08-13 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019094648A1
(en)
|
2017-11-08 |
2019-05-16 |
L.E.A.F. Holdings Group Llc |
Platinum complexes and uses thereof
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
WO2019126709A1
(en)
|
2017-12-22 |
2019-06-27 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
CN111954531A
(zh)
|
2018-02-07 |
2020-11-17 |
L.E.A.F.控股集团公司 |
α聚谷氨酸化培美曲塞及其用途
|
|
CN111954530A
(zh)
|
2018-02-07 |
2020-11-17 |
L.E.A.F.控股集团公司 |
γ聚谷氨酸化培美曲塞及其用途
|
|
WO2019197845A1
(en)
|
2018-04-12 |
2019-10-17 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US12458597B2
(en)
|
2018-05-03 |
2025-11-04 |
L.E.A.F. Holdings Group Llc |
Carotenoid compositions and uses thereof
|
|
EP3807413B1
(en)
|
2018-06-18 |
2025-05-21 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
EP3833761A1
(en)
|
2018-08-07 |
2021-06-16 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
US12421507B2
(en)
|
2018-08-20 |
2025-09-23 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of CRISPR-CAS9
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
AU2019347774A1
(en)
|
2018-09-28 |
2021-03-25 |
Nutcracker Therapeutics, Inc. |
Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
|
|
EP4379053A3
(en)
|
2018-10-09 |
2024-09-18 |
The University of British Columbia |
Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
|
|
WO2020097540A1
(en)
|
2018-11-09 |
2020-05-14 |
Arbutus Biopharma Corporation |
Lipid nanoparticle formulations
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
AU2019410737A1
(en)
|
2018-12-21 |
2021-06-10 |
CureVac SE |
RNA for malaria vaccines
|
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CA3125511A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
JP7744011B2
(ja)
|
2019-06-07 |
2025-09-25 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたｃａｓｘシステム
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
ES2982157T3
(es)
|
2019-07-18 |
2024-10-14 |
Institut Nat De La Sante Et De Larecherche Medicale Inserm |
Mutante de RAC2 para su uso en la ablación de la hematopoyesis y en el tratamiento de neoplasias malignas hematopoyéticas
|
|
EP3999642A1
(en)
|
2019-07-19 |
2022-05-25 |
Flagship Pioneering Innovations VI, LLC |
Recombinase compositions and methods of use
|
|
EP4010031A1
(en)
|
2019-08-06 |
2022-06-15 |
L.E.A.F Holdings Group LLC |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
|
HRP20241255T1
(hr)
|
2019-08-14 |
2024-12-06 |
Acuitas Therapeutics, Inc. |
Poboljšane lipidne nanočestice za isporuku nukleinskih kiselina
|
|
CA3144902A1
(en)
|
2019-08-14 |
2022-01-19 |
Andreas Thess |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
CN110564729A
(zh)
*
|
2019-09-17 |
2019-12-13 |
四川大学 |
一种对PLK1基因具有沉默活性且具有高血清稳定性的siRNA及其应用
|
|
CN120423969A
(zh)
|
2019-09-19 |
2025-08-05 |
摩登纳特斯有限公司 |
用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
|
|
JP2022548399A
(ja)
|
2019-09-23 |
2022-11-18 |
オメガ セラピューティクス， インコーポレイテッド |
肝細胞核因子４－アルファ（ＨＮＦ４α）遺伝子発現をモジュレートするための組成物および方法
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
CA3160511A1
(en)
|
2020-02-04 |
2021-08-12 |
Susanne RAUCH |
Coronavirus vaccine
|
|
US11965161B2
(en)
|
2020-03-04 |
2024-04-23 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for sensitization of tumor cells to immune therapy
|
|
JP2023517326A
(ja)
|
2020-03-11 |
2023-04-25 |
オメガ セラピューティクス， インコーポレイテッド |
フォークヘッドボックスｐ３（ｆｏｘｐ３）遺伝子発現をモジュレートするための組成物および方法
|
|
MX2022011805A
(es)
|
2020-03-24 |
2023-01-11 |
Generation Bio Co |
Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
|
|
CN115667531A
(zh)
|
2020-03-24 |
2023-01-31 |
世代生物公司 |
非病毒DNA载体和其用于表达戈谢（Gaucher）治疗剂的用途
|
|
WO2021198157A1
(en)
|
2020-03-30 |
2021-10-07 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
CN116322760A
(zh)
|
2020-05-20 |
2023-06-23 |
旗舰创业创新第六有限责任公司 |
冠状病毒抗原组合物及其用途
|
|
IL298363A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
EP4158032A2
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
CA3170740A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
IL298539A
(en)
|
2020-05-29 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Trem compositions and methods relating thereto
|
|
MX2022016332A
(es)
|
2020-06-15 |
2023-04-03 |
Res Inst Nationwide Childrens Hospital |
Administracion de vectores de virus adenoasociados para distrofias musculares.
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
FI4182297T3
(fi)
|
2020-07-16 |
2025-12-05 |
Acuitas Therapeutics Inc |
Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
|
|
BR112023001648A2
(pt)
|
2020-07-27 |
2023-04-04 |
Anjarium Biosciences Ag |
Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
CA3189854A1
(en)
|
2020-08-06 |
2022-02-10 |
Modernatx, Inc. |
Compositions for the delivery of payload molecules to airway epithelium
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
IL300947A
(en)
|
2020-09-03 |
2023-04-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
JP2023549011A
(ja)
|
2020-09-15 |
2023-11-22 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
遺伝子編集のための脂質製剤
|
|
MX2023004371A
(es)
|
2020-10-14 |
2023-07-26 |
George Mason Res Foundation Inc |
Lípidos ionizables, y métodos de fabricación y uso de los mismos.
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
|
GB2616584A
(en)
|
2020-12-03 |
2023-09-13 |
Scribe Therapeutics Inc |
Engineered class 2 type V CRISPR systems
|
|
PH12023500013A1
(en)
*
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US20240175020A1
(en)
|
2020-12-23 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
EP4314292A1
(en)
|
2021-03-26 |
2024-02-07 |
MiNA Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
|
JP2024511206A
(ja)
|
2021-03-26 |
2024-03-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
JP2024517427A
(ja)
|
2021-04-20 |
2024-04-22 |
アンジャリウム バイオサイエンシズ エージー |
アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
|
|
CA3216585A1
(en)
|
2021-04-27 |
2022-11-03 |
Nathaniel SILVER |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
WO2022233880A1
(en)
|
2021-05-03 |
2022-11-10 |
Curevac Ag |
Improved nucleic acid sequence for cell type specific expression
|
|
EP4352215A1
(en)
|
2021-06-11 |
2024-04-17 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
WO2023014974A1
(en)
|
2021-08-06 |
2023-02-09 |
University Of Iowa Research Foundation |
Double stranded mrna vaccines
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
AU2022336664A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
JP2024533865A
(ja)
|
2021-09-14 |
2024-09-12 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
環状脂質及びその使用方法
|
|
TW202325263A
(zh)
|
2021-09-14 |
2023-07-01 |
美商雷納嘉德醫療管理公司 |
非環狀脂質及其使用方法
|
|
JP2024534428A
(ja)
|
2021-09-17 |
2024-09-20 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
環状ポリリボヌクレオチドを生成するための組成物及び方法
|
|
US20240392271A1
(en)
|
2021-09-21 |
2024-11-28 |
Scribe Therapeutics Inc. |
Engineered casx repressor systems
|
|
MX2024004618A
(es)
|
2021-10-18 |
2024-07-12 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y metodos para purificar polirribonucleotidos.
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
CN118829423A
(zh)
|
2021-11-12 |
2024-10-22 |
摩登纳特斯有限公司 |
用于将有效载荷分子递送至气道上皮的组合物
|
|
CN118829625A
(zh)
|
2021-11-16 |
2024-10-22 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及它们的使用方法
|
|
JP2024542260A
(ja)
|
2021-11-22 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
KR20240125931A
(ko)
|
2021-11-24 |
2024-08-20 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
수두-대상포진 바이러스 면역원 조성물 및 이의 용도
|
|
MX2024006440A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones inmunogenicas y sus usos.
|
|
US20250352638A1
(en)
|
2021-11-24 |
2025-11-20 |
Flagship Pioneering Innovations Vi, Llc |
Coronavirus immunogen compositions and their uses
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
US12129223B2
(en)
|
2021-12-16 |
2024-10-29 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
TW202340460A
(zh)
|
2021-12-17 |
2023-10-16 |
美商旗艦先鋒創新有限責任公司 |
用於在變性條件下富集環狀ｒｎａ之方法
|
|
KR20240117149A
(ko)
|
2021-12-22 |
2024-07-31 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
CA3243054A1
(en)
|
2021-12-23 |
2025-04-08 |
Renagade Therapeutics Management Inc. |
Constrained Lipids and Associated Utilization Processes
|
|
EP4452337A1
(en)
|
2021-12-23 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
EP4463475A2
(en)
|
2022-01-14 |
2024-11-20 |
Anjarium Biosciences AG |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
JP2025502257A
(ja)
|
2022-01-17 |
2025-01-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
固形腫瘍細胞の集団の細胞死を誘導する方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4469063A1
(en)
|
2022-01-27 |
2024-12-04 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
EP4475882A1
(en)
|
2022-02-09 |
2024-12-18 |
ModernaTX, Inc. |
Mucosal administration methods and formulations
|
|
WO2023152365A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the 15-lipoxygenase for the treatment of lymphedema
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
KR20240161965A
(ko)
|
2022-03-14 |
2024-11-13 |
제너레이션 바이오 컴퍼니 |
이종 프라임 부스트 백신 조성물 및 사용 방법
|
|
WO2023178425A1
(en)
|
2022-03-23 |
2023-09-28 |
Nanovation Therapeutics Inc. |
High sterol-containing lipid nanoparticles
|
|
KR20240166554A
(ko)
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
CA3255116A1
(en)
|
2022-04-01 |
2023-10-05 |
Nanovation Therapeutics Inc. |
METHOD FOR ADMINISTRATING RNA AND ASSOCIATED COMPOSITION
|
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
AU2023260227A1
(en)
|
2022-04-27 |
2024-11-21 |
Shanghai Regenelead Therapies Co., Ltd |
Nucleic acid construct and use thereof
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
JP2025515206A
(ja)
|
2022-05-13 |
2025-05-13 |
上海瑞宏迪医薬有限公司 |
Ｕｔｒを含む核酸構築物及びその使用
|
|
EP4522753A2
(en)
|
2022-05-13 |
2025-03-19 |
Flagship Pioneering Innovations VII, LLC |
Double stranded dna compositions and related methods
|
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
CA3256897A1
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for the administration of nucleic acids and their methods of use
|
|
WO2023230295A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
Rna compositions for delivery of monkeypox antigens and related methods
|
|
CN119562807A
(zh)
|
2022-05-30 |
2025-03-04 |
生物技术公司 |
用于递送核酸的复合物
|
|
JP2025520127A
(ja)
|
2022-06-02 |
2025-07-01 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたクラス２タイプｖ ｃｒｉｓｐｒ系
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Compositions of lipid nanoparticles and their uses
|
|
CA3257914A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
COMPOSITIONS AND METHODS FOR TARGETING PCSK9
|
|
EP4536819A1
(en)
|
2022-06-07 |
2025-04-16 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
WO2024023034A1
(en)
|
2022-07-25 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Use of apelin for the treatment of lymphedema
|
|
TW202413424A
(zh)
|
2022-08-01 |
2024-04-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節蛋白及相關方法
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
AU2023323547A1
(en)
|
2022-08-12 |
2025-03-20 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
WO2024049979A2
(en)
|
2022-08-31 |
2024-03-07 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|
|
IL319414A
(en)
|
2022-09-23 |
2025-05-01 |
BioNTech SE |
Compositions for delivering antigens at the liver level and related methods
|
|
WO2024064910A1
(en)
|
2022-09-23 |
2024-03-28 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
AU2023347390A1
(en)
|
2022-09-23 |
2025-04-10 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
AU2023353931A1
(en)
|
2022-09-26 |
2025-03-20 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
AU2023357320A1
(en)
|
2022-10-06 |
2025-04-17 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
KR20250099195A
(ko)
|
2022-10-31 |
2025-07-01 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
AU2023375897A1
(en)
|
2022-11-08 |
2025-06-12 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
AR131008A1
(es)
|
2022-11-08 |
2025-02-05 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
JP2025541726A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェネレーション バイオ カンパニー |
細胞標的化のためのステルス脂質ナノ粒子組成物
|
|
KR20250129819A
(ko)
|
2022-12-01 |
2025-08-29 |
제너레이션 바이오 컴퍼니 |
핵산, 이온화 가능한 지질, 스테롤, 지질에 고정된 중합체, 및 헬퍼 지질을 포함하는 지질 나노입자 및 이의 용도
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
WO2024119051A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2024123633A1
(en)
|
2022-12-08 |
2024-06-13 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
EP4630033A1
(en)
|
2022-12-09 |
2025-10-15 |
Institut National de la Santé et de la Recherche Médicale |
Novel human antiviral genes related to the eleos and lamassu prokaryotic systems
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
CN121127490A
(zh)
|
2022-12-28 |
2025-12-12 |
生物技术欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
EP4648789A1
(en)
|
2023-01-09 |
2025-11-19 |
Institut National de la Santé et de la Recherche Médicale |
Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating adverse post-ischemic cardiac remodeling in a patient who experienced a myocardial infarction
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
WO2024153636A1
(en)
|
2023-01-17 |
2024-07-25 |
Institut National de la Santé et de la Recherche Médicale |
Vasorin as a biomarker and biotarget in nephrology
|
|
EP4654984A1
(en)
|
2023-01-27 |
2025-12-03 |
Institut National de la Santé et de la Recherche Médicale |
Use of amphiregulin (areg) in methods of treating vascular hyperpermeability
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
IL322468A
(en)
|
2023-02-13 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
EP4665405A1
(en)
|
2023-02-17 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Dna compositions comprising modified uracil
|
|
AU2024220221A1
(en)
|
2023-02-17 |
2025-08-07 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
DE112024001143T5
(de)
|
2023-03-08 |
2025-12-18 |
CureVac SE |
Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
KR20250162610A
(ko)
|
2023-03-15 |
2025-11-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
|
|
WO2024194484A1
(en)
|
2023-03-23 |
2024-09-26 |
Institut National de la Santé et de la Recherche Médicale |
Modulating the expression and/or activity of gas7 for modulating viral replication
|
|
TW202444914A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
抑制子融合蛋白系統
|
|
TW202444906A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向pcsk9之組合物及方法
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202444921A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向lpa之組合物及方法
|
|
TW202444910A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
編碼casx之信使rna
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
AU2024252590A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
CN121038807A
(zh)
|
2023-05-03 |
2025-11-28 |
生物技术欧洲股份公司 |
优化的csp变体及相关方法
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024335A2
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025021083A1
(en)
*
|
2023-07-24 |
2025-01-30 |
National Institute Of Biological Sciences, Beijing |
Lipid nanoparticle compositions for localized treatment of skin diseases
|
|
TW202516001A
(zh)
|
2023-07-25 |
2025-04-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
Ｃａｓ內切酶及相關方法
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
TW202519509A
(zh)
|
2023-08-01 |
2025-05-16 |
德商拜恩技術股份公司 |
可離子化硫脂質及其用途
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025046121A1
(en)
|
2023-09-01 |
2025-03-06 |
Novoarc Gmbh |
Lipid nanoparticle with nucleic acid cargo and ionizable lipid
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072293A1
(en)
|
2023-09-27 |
2025-04-03 |
Scribe Therapeutics Inc. |
Optimized mrnas encoding casx proteins
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025083211A1
(en)
|
2023-10-20 |
2025-04-24 |
Institut National de la Santé et de la Recherche Médicale |
Use of factor h for the treatment of dementia
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
TW202535835A
(zh)
|
2023-11-14 |
2025-09-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025215072A1
(en)
|
2024-04-10 |
2025-10-16 |
Institut National de la Santé et de la Recherche Médicale |
Class i lanthipeptides with anti-viral function
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025248096A1
(en)
|
2024-05-31 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Antimicrobial peptides having liquid-liquid phase separation activities
|
|
WO2025259931A1
(en)
|
2024-06-14 |
2025-12-18 |
Orbital Therapeutics, Inc. |
Compositions and methods for rna circularization
|